Proveca
Proveca is a UK-based specialty pharmaceutical company founded in 2010 that develops and licenses age-appropriate medicines for children, focusing on paediatric neurology and cardiology through the EMA PUMA regulatory pathway across Europe and select international markets.
- Company typePrivate
- Founded2010
- HeadquartersHalton, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Proveca does
Proveca is a UK-based specialty pharmaceutical company founded in 2010 by Simon Bryson and Helen Shaw, exclusively focused on developing and licensing age-appropriate medicines for children. The company addresses the systemic problem that approximately half of medicines administered to children are in the wrong format or unlicensed for paediatric use, leading to safety and adherence risks. Proveca targets two therapeutic areas — neurology (chronic neurological disorders including cerebral palsy and epilepsy-related sialorrhoea) and cardiology (paediatric heart failure, hypertension, and oedema) — where approximately 80% of children with heart failure currently receive off-label adult medications. The company has contributed to 5 of the 10 PUMAs ever granted globally.
The core technology centres on proprietary orodispersible tablet formulations designed specifically for paediatric administration, including 2mm mini-tablets (Aqumeldi) and score-line tablets enabling accurate 2.5mg dosing (Bopediat). Three core products are Sialanar® (glycopyrronium bromide) for severe sialorrhea in children with chronic neurological disorders, Aqumeldi® (enalapril maleate) for paediatric heart failure, and Bopediat® (furosemide) pending European Commission approval. The pipeline includes Captopril, additional Enalapril and Furosemide protocols.
The business model is licensing-based commercialisation through the EMA PUMA pathway. Proveca generates revenue from product sales across direct sales channels in the EU and UK, plus distribution partnerships internationally (Tamro/Oriola for Nordics, Eurocept for Netherlands, BCWorld Healthcare for South Korea, and regional distributors in Eastern Europe and Latin America). Customer segments are paediatric healthcare providers (hospitals, paediatricians, neurologists, cardiologists), with end beneficiaries being children from birth to under 18 years. The company is venture capital-backed by AlbionVC and Catapult Ventures, operates through wholly-owned subsidiaries in the UK, Ireland, Germany, Italy, and France, and is pursuing US market entry via an FDA NDA for Aqumeldi submitted in March 2026.
Proveca firmographics
Firmographics- Name
- Proveca
- Legal name
- Proveca Ltd
- Website
- https://proveca.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Proveca is a UK-based specialty pharmaceutical company founded in 2010 that develops and licenses age-appropriate medicines for children, focusing on paediatric neurology and cardiology through the EMA PUMA regulatory pathway across Europe and select international markets.
- Ownership category
- akta.pro rank
Proveca industry classification
Industry- Product category
- Pediatric Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)
- akta.pro secondary industry
- Regulatory Affairs, Labeling & Advertising/Promotion Compliance (HLAJADAI)
Keywords
Where Proveca is headquartered
LocationHeadquarters
- HQ city
- Halton
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Proveca business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Marketing or Sales, Personnel, Supply Chain
Revenue model
- Product sales - Sialanar: Proveca generates revenue from commercialising licensed paediatric medicines. Sialanar® (glycopyrronium bromide) is marketed for neurological conditions including chronic drooling in children with neurological disorders.
- Product sales - Aqumeldi: Aqumeldi® (enalapril maleate) is commercialised for paediatric heart failure in Europe and UK, with NDA submitted to FDA for US market expansion.
- Product sales - Bopediat: Bopediat® (furosemide) orodispersible tablets received positive EMA opinion for PUMA, pending European Commission approval for treatment of oedema and hypertension in children.
Go-to-market motion2 records
Distribution channels5 records
Marketing channels4 records
Proveca product offering
Product offeringCore offering
Proveca is a global pharmaceutical company that develops and licenses age-appropriate medicines for children in neurology and cardiology therapy areas. The company identifies off-patent medicines with unmet paediatric healthcare needs and obtains Paediatric Use Marketing Authorisations (PUMA) and other marketing authorisations to bring licensed paediatric formulations such as Sialanar® (glycopyrronium bromide), Aqumeldi® (enalapril maleate), and Bopediat® (furosemide) to market.
Product overview
Proveca is a pharmaceutical company specialising in the development and licensing of medicines for children. The company focuses on identifying off-patent medicines with unmet priority healthcare needs in the paediatric market, obtaining paediatric licences through the PUMA (Paediatric Use Marketing Authorisation) pathway and national marketing authorisations. Current approved products include Sialanar® (glycopyrronium bromide) for neurological conditions causing chronic drooling/sialorrhea, and Aqumeldi® (enalapril maleate) for cardiology conditions. Bopediat® (furosemide) is pending European Commission approval. The product portfolio spans neurology and cardiology therapy areas, with medicines designed in age-appropriate formats such as orodispersible tablets.
Differentiator
Problem solved
Functional benefit
Brands
- Bopediat®: Furosemide orodispersible tablets for treatment of oedema and hypertension in children from birth to less than 18 years
- Sialanar®
- Aqumeldi®
Products and services
- Sialanar® Glycopyrronium bromide 400mcg/ml oral solution indicated for symptomatic treatment of severe sialorrhea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders. Licensed via PUMA and launched across multiple European markets, South Korea, and South America.
- Aqumeldi® Enalapril maleate orodispersible mini tablet (0.25mg and 1mg) indicated for treatment of heart failure in children from birth to less than 18 years, and for treatment of hypertension. Licensed for paediatric heart failure in Europe and UK, with NDA submitted to FDA for US market expansion.
- Bopediat® Furosemide 5mg orodispersible tablet with functional score line enabling accurate 2.5mg doses. Indicated in children from birth to less than 18 years for treatment of oedema of cardiac or renal origin, oedema of hepatic origin, and hypertension in patients with chronic kidney disease. Awaiting European Commission approval.
Quantifiable outcome
- 80% of children with heart failure currently receive off-label adult medications
- +2 more outcomes
Companies that use Proveca
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
Proveca technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Proveca partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and supporting.
- BCWorld HealthcarecoreIn March 2024, Proveca entered into a partnership agreement with BCWorld Healthcare, granting exclusive rights for licensing and distribution of Sialanar® in South Korea. BCWorld submitted NDA in October 2024 and received marketing authorisation from MFDS in August 2025. The product launched in South Korea in March 2026 for treatment of severe sialorrhea in children aged 3 years and older with chronic neurological disorders.
- Aston UniversitysupportingProveca partnered with Aston University to support final research projects for MSc Pharmaceutical Sciences, Drug Delivery and MPharm students. The partnership includes PhD sponsorship, research supervision, workshops on drug formulation challenges, and student project support. Joint work explores development of drug formulations.
- Alder Hey Children's HospitalcoreCollaboration between Alder Hey Children's Hospital and Proveca Ltd to improve children's medicines. The partnership aims to provide the best pharmaceutical treatments for children by identifying existing gaps and developing new products specifically for children and young people. Alder Hey brings expertise in paediatric healthcare and their NIHR-funded Clinical Research Facility.
- Tamro ABsupportingTamro AB manages distribution of Proveca medicines to Norway, Sweden, Denmark, and Iceland, supplying these countries via local wholesalers.
- Oriola ABsupportingOriola AB is responsible for Proveca Pharma Ltd's regulatory, quality, and pharmacovigilance obligations in the Nordic region.
- Eurocept PharmaceuticalssupportingEurocept Pharmaceuticals handles adverse event reporting and product distribution for Sialanar® and Aqumeldi® products in the Netherlands.
- European Medicines Agency (EMA)coreProveca works with EMA for regulatory approvals through the Paediatric Use Marketing Authorisation (PUMA) pathway. EMA CHMP adopted positive opinion for Bopediat® in March 2026.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Proveca competitors and assessment
Company assessmentDirect peers
- Swedish Orphan Biovitrum (Sobi): Swedish Orphan Biovitrum is a European specialty pharmaceutical company focused on rare diseases and specialty medicines, including paediatric indications. Sobi's commercial model of licensing, developing, and distributing niche specialty medicines across global markets closely parallels Proveca's paediatric pharmaceutical strategy, though Sobi operates at significantly larger scale.
- ADVANZ PHARMA (formerly Concordia International): ADVANZ PHARMA is a specialty pharmaceutical company focused on niche and differentiated medicines for complex diseases, including hospital and specialty pharmaceuticals across Europe. Their model of licensing, developing, and commercializing specialty medicines in European and international markets directly parallels Proveca's paediatric pharmaceutical strategy.
- Norgine: Norgine is a European specialty pharmaceutical company that develops, licenses, and commercializes innovative medicines across various therapeutic areas, including gastroenterology and other specialties. Norgine's European commercial infrastructure and specialty pharma licensing model closely resembles Proveca's distribution and licensing approach.
- Clinigen Group: Clinigen Group is a UK-based specialty pharmaceutical company that provides access to medicines through licensing, distribution, and clinical trial supply services. Clinigen's model of managing medicine access across multiple geographies and therapeutic areas closely parallels Proveca's distribution and licensing infrastructure approach.
Broad incumbents
- Jazz Pharmaceuticals: Jazz Pharmaceuticals acquired GW Pharmaceuticals, which developed cannabinoid-based paediatric epilepsy treatments, demonstrating a similar specialty pharma model of developing differentiated paediatric formulations for neurological conditions. Jazz represents a broader incumbent player with paediatric neurology exposure and significant commercial scale.
- BioMarin Pharmaceutical: BioMarin is a specialty biopharmaceutical company focused on rare diseases, with several paediatric products across multiple therapeutic areas including neurology and cardiology. BioMarin's paediatric rare disease franchise, combined with global commercial infrastructure, makes it a comparable incumbent peer in paediatric specialty pharma, though at substantially larger scale.
- Mallinckrodt Pharmaceuticals: Mallinckrodt is a specialty pharmaceutical company that develops and commercializes medicines across multiple therapeutic areas including neurology and cardiology, with paediatric formulations in their portfolio. While significantly larger than Proveca, Mallinckrodt represents a broader incumbent with overlapping therapeutic focus areas.
- Aspen Pharmacare: Aspen Pharmacare is a global specialty and generic pharmaceutical company with significant presence in emerging markets and a paediatric pharmaceutical portfolio. Aspen's model of distributing specialty and generic medicines across multiple geographies, including emerging markets, provides a comparable distribution and licensing pattern to Proveca's international expansion.
Emerging players
- Orchard Therapeutics: Orchard Therapeutics is a biotechnology company developing gene therapies for rare paediatric diseases, including neurological conditions. While Orchard operates in a different therapeutic modality (gene therapy vs. reformulated small molecules), both companies target severe paediatric conditions with limited treatment options and pursue regulatory pathways specifically designed for paediatric populations.
- Theravance Biopharma: Theravance Biopharma is a specialty pharmaceutical company focused on developing and commercializing medicines for serious diseases, including respiratory and gastrointestinal conditions. While operating at a different scale and therapeutic focus, Theravance represents a comparable specialty pharma model of developing differentiated medicines for specific patient populations.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Proveca social profiles
Digital presenceProveca financial estimates
Financial estimateRevenue estimate
Valuation estimate
Proveca leadership team
Management profileNumber of profiles
Profiles6 records
Proveca subsidiaries and ownership
Company hierarchySubsidiaries4 records
Proveca funding detail
Funding detailFunding overview
Funding rounds3 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Proveca M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Proveca
What does Proveca do?
Proveca is a global pharmaceutical company that develops and licenses age-appropriate medicines for children in neurology and cardiology therapy areas. The company identifies off-patent medicines with unmet paediatric healthcare needs and obtains Paediatric Use Marketing Authorisations (PUMA) and other marketing authorisations to bring licensed paediatric formulations such as Sialanar® (glycopyrronium bromide), Aqumeldi® (enalapril maleate), and Bopediat® (furosemide) to market.
Is Proveca a public or private company?
Proveca is a private company. It is classified as venture growth investor backed and is currently operating.
When was Proveca founded?
Proveca was founded in 2010. It employs 1 to 10 people.
Where is Proveca based?
Proveca is headquartered in Halton, United Kingdom, in the Europe region.
How does Proveca make money?
Three revenue lines are on record. Product sales - Sialanar is the primary driver. The others are product sales - Aqumeldi and product sales - Bopediat.
Who are Proveca's main competitors?
Direct peers on record are Swedish Orphan Biovitrum (Sobi), ADVANZ PHARMA (formerly Concordia International), Norgine and Clinigen Group. Broad incumbents are Jazz Pharmaceuticals, BioMarin Pharmaceutical, Mallinckrodt Pharmaceuticals and Aspen Pharmacare. Emerging players are Orchard Therapeutics and Theravance Biopharma.
Does Proveca have an API?
No public API is recorded for Proveca.
What industry is Proveca in?
Proveca's product category is Pediatric Pharmaceuticals. Its primary akta.pro industry code is HLAIALAH, Regulatory Strategy & IND/NDA/BLA Submissions Support, with a secondary code of HLAJADAI, Regulatory Affairs, Labeling & Advertising/Promotion Compliance. Its NAICS code is 3254 and its SIC code is 2834.